The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
The price increases are due to the rising costs of raw materials.
The jump in profit is due to the better performance of the API business.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
Subscribe To Our Newsletter & Stay Updated
